freeze-thaw cycle is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
=== Alcoholic beverages === In 2023, Monster launched the Monster Beast line of alcoholic beverages. The first release, The Beast Unleashed, featured flavors inspired by classic Monster Energy drinks but reformulated without sugar or caffeine, and brewed with alcohol at 6.0% alcohol by volume. The Beast Unleashed flavors include:
=== Development === On January 31, 2023, it was announced that a remake version of Matlock was in development, and Jennie Snyder Urman signed on to write a pilot episode to be aired by CBS. Urman is expected to executive produce alongside Joanna Klein, Eric Christian Olsen, and Kathy Bates. On May 9, 2023, the Matlock remake was given a series order. The series is developed by Urman. John Will and Kat Coiro were added as executive producers. Coiro also directed the pilot. Production companies involved with the series are Sutton Street, Cloud Nine, and CBS Studios. Matlock was moved to the 2024–25 season due to strike-related production delays. It was later reported that it was a 19-episode order. On October 22, 2024, CBS renewed the series for a second season. Though set in New York City, the show is filmed at Paramount Studios in California after the pilot was shot in Toronto. On January 22, 2026, CBS renewed the series for a third season.
=== Difficulties === Extremely large breasts are a source of considerable attention. Some women try to hide or mask their breasts with special clothing, including minimizing bras or breast binding clothing. Women with this condition may be subject to psychological problems due to unwanted attention or harassment. Depression is common in those affected. In the case of a 12-year-old Japanese girl reported in 1993, her "massively enlarged" breasts caused her "intense psychological problems, incapacitating her in school activities and social relations". Actress Soleil Moon Frye, who starred as a child in the sitcom Punky Brewster, reported in an interview with People magazine that boys taunted her, calling her "Punky Boobster". It affected her professional and social life negatively. "People started to think of me as a bimbo," she said in the interview. "I couldn't sit up straight without people looking at me like I was a prostitute[.]" She had breast reduction surgery at the age of 15. Finding large bra sizes and styles that fit is challenging. Also, larger bras are more costly, challenging to find, and unflattering to the wearer. Ill-fitting bras with narrow straps can cause chronic irritation, redness, and indentations in the shoulders. Skin rashes under the breasts are common, particularly during warm weather. Heavy breasts may cause headaches, neck pain, upper and lower back pain, and numbness or tingling in the fingers. There is a possible connection between macromastia and carpal-tunnel-syndrome.
Sources: en.wikipedia.org
Wolverine's primary mutant power is an accelerated healing process, typically referred to as his mutant "healing factor", that regenerates damaged or destroyed tissues of his body far beyond that of normal humans. In addition to accelerated healing of physical traumas, Wolverine's healing factor makes him extraordinarily resistant to diseases, drugs and toxins. As a result of this ability, Wolverine has the appearance of a man in his early forties, although he is more than 100 years old. Wolverine's healing factor also affects a number of his physical attributes by increasing them to superhuman levels. His stamina is sufficiently heightened to the point that he can exert himself for hours. Wolverine's agility and reflexes are also enhanced to levels that are beyond the physical limits of the finest human athlete. Due to his healing factor's constant regenerative qualities, he can push his muscles beyond the limits of the human body without injury. Wolverine also has superhuman strength. The Muramasa blade, a katana of mystic origins that can inflict wounds that nullify superhuman healing factors, can suppress Wolverine's powers. Wolverine's senses of sight, smell, and hearing are super-humanly acute. He can see with perfect clarity at greater distances than an ordinary human, even in near-total darkness. His hearing is enhanced in a similar manner, allowing him to hear sounds ordinary humans cannot and hear across greater distances; he can hear the heartbeats of hostile living beings before conflict begins.
The original capital of the islands was at Port Louis to the north of the present site of Stanley, on Berkeley Sound. Captains Francis Crozier and James Clark Ross were recruited by Governor Richard Moody in his quest to find a new capital for The Falklands. Both Crozier and Ross (who are remembered in Crozier Place and Ross Road in Stanley) were among the Royal Navy's most distinguished seafarers. They spent five months in the islands with their ships Terror and Erebus, later lost looking for the Northwest Passage. Governor Moody (after whom Moody Brook is named), however, decided to move the capital to Port Jackson, which was renamed "Stanley Harbour", after a survey. Stanley Harbour was considered to have a deeper anchorage for visiting ships. Not all the inhabitants were happy with the change; a JW Whitington is recorded as saying, "Of all the miserable bog holes, I believe that Mr Moody has selected one of the worst for the site of his town."
== Diagnosis == Diagnosing hyperandrogenism can be complex due to the wide variety and severity of signs and symptoms that may present. It is most often diagnosed by checking for signs of hirsutism according to a standardized method that scores the range of excess hair growth. Girls may show symptoms of hyperandrogenism early in life, but physicians become more concerned when the patient is in her late teens or older. Checking medical history and a physical examination of symptoms are used for an initial diagnosis. Patient history assessed includes age at thelarche, adrenarche, and menarche; patterns of menstruation; obesity; reproductive history; and the start and advancement of hyperandrogenism symptoms. Patterns of menstruation are examined since irregular patterns may accompany hyperandrogenism. Other conditions that may present alongside hirsutism that can contribute to diagnosis include androgenic alopecia and acne. If hyperandrogenism is severe, virilization may occur. Family history is also assessed for occurrences of hyperandrogenism symptoms or obesity in other family members. Laboratory tests can measure FSH, luteininzing hormone, DHEAS, prolactin, 17α-hydroxyprogesterone, and total and free testosterone in the blood. Abnormally high levels of any of these hormones help in diagnosing hyperandrogenism.
Sources: en.wikipedia.org
For example, lung resistance-related proteins, otherwise referred to as major vault proteins, are located on the nuclear membrane of cells and typically mediate nucleocytoplasmic transport. Here, the regulation of compounds between the nucleus and cytoplasm is a process that can be overexpressed by cancer cells to transport DNA-targeted chemotherapeutic drugs away from the nucleus, and essentially restrict these drugs from successfully interacting with their targets. Without reducing the total intracellular chemotherapeutic drug concentration, cancer cells have developed mechanisms to successfully dismantle drug-target interactions and confer resistance to multiple chemotherapeutic drugs. An additional mechanism of resistance interfering with drug-target interaction can be demonstrated by mutations in genes that encode for drug target proteins, such as tubulin. Broadly, tubulin proteins make up intracellular structures known as microtubules that play a fundamental role in cellular shape, division, signaling, and movement, thus making them a particular promising site of target for chemotherapeutic drugs. By altering or inhibiting microtubule dynamics in cancer cells, drugs can prohibit successfully cell division and induce the direct activation of adoptotic pathways. However, mutations that produce physical alterations in tubulin protein structure, can interfere with the several tubulin binding sites and inhibit the effective interaction and activity of these chemotherapeutic drugs.
== Patents == Robert B. Cody and James A. Laramee, “Method for atmospheric pressure ionization” U.S. patent 6,949,741 issued September 27, 2005. (Priority date: April 2003). James A. Laramee and Robert B. Cody “Method for Atmospheric Pressure Analyte Ionization” U.S. patent 7,112,785 issued September 26, 2006.
== Application == One of the primary applications of hybrid containers is in pharmaceutical cold-chain logistics to keep pharmaceutical products, such as vaccines or active ingredients, within strict temperature ranges. Currently, this technology is only being used in a limited number of shipping containers. Examples of hybrid shipping container systems include SkyCell 1500X, SkyCell 6500X, va-Q-tec va-Q-one, and Tower Cold Chain KTEvolution. Other temperature-controlled container providers, including Peli BioThermal and World Courier, offer solutions incorporating thermal energy storage and advanced insulation technologies.
Significant mathematics began in India in the first millennium BCE. The Śulba Sūtras (literally, "Aphorisms of the Chords" in Vedic Sanskrit) (c. 700–400 BCE) contain the earliest extant verbal expression of the Pythagorean theorem (although very likely it had been known to the Old Babylonians.) All mathematical works were orally transmitted until approximately 500 BCE; thereafter, they were transmitted both orally and in manuscript form. The oldest extant mathematical document produced on the Indian subcontinent is the birch bark Bakhshali manuscript from the 7th century CE. During the classical period of Indian mathematics (400 CE to 1200 CE), Aryabhata, Brahmagupta, Bhaskara II, Varāhamihira, and Madhava made important contributions. The decimal number system in use today was first recorded in Indian mathematics. Indian mathematicians made early contributions to the study of the concept of zero as a number, negative numbers, arithmetic, and algebra. Trigonometry was further advanced in India, and the modern definitions of sine and cosine were developed there. These mathematical concepts were transmitted to the Middle East, China, and Europe. A later landmark in Indian mathematics was the development of the series expansions for trigonometric functions (sine, cosine, and arc tangent) by mathematicians of the Kerala school in the 15th century CE. Their work, completed two centuries before the invention of calculus in Europe, provided the first example of a power series. In the modern era, Srinivasa Ramanujan made fundamental contributions to number theory.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.